| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Doxorubicin | CTRPv2 | pan-cancer | AAC | -0.0034 | 0.9 |
| mRNA | AG-014699 | GDSC1000 | pan-cancer | AAC | -0.0035 | 0.9 |
| mRNA | TL-2-105 | GDSC1000 | pan-cancer | AAC | 0.0034 | 0.9 |
| mRNA | BRD-K92856060 | CTRPv2 | pan-cancer | AAC | 0.0039 | 0.9 |
| mRNA | R428 | CTRPv2 | pan-cancer | AAC | -0.0046 | 0.9 |
| mRNA | 17-AAG | CCLE | pan-cancer | AAC | 0.0045 | 0.9 |
| mRNA | MK-2206 | GDSC1000 | pan-cancer | AAC | -0.0035 | 0.9 |
| mRNA | SU11274 | CTRPv2 | pan-cancer | AAC | 0.0035 | 0.9 |
| mRNA | PIK-93 | GDSC1000 | pan-cancer | AAC | 0.0026 | 0.9 |
| mRNA | ISOX:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0034 | 0.9 |